BACKGROUND: The purpose of this study was to compare demographic factors and 1-year treatment outcomes of patients treated with buprenorphine or methadone. METHODS: The study included 252 subjects who received a prescription for buprenorphine in an academic internal medicine practice and 252 subjects who enrolled in a methadone maintenance program located on the same campus over the same time frame. Data were collected retrospectively. Patients were classified as "opioid-positive" or "opioid-negative" each month for a year based on urine drug testing and provider assessment. Successful treatment was defined as remaining in treatment after 1 year and achieving 6 or more opioid-negative months. RESULTS: Buprenorphine patients were more likely to be male, have health insurance, be employed, abuse prescription opioids, and be human immunodeficiency virus (HIV) infected; they were less likely to abuse benzodiazepines. At 12 months, 140 (55.6%) of buprenorphine patients and 156 (61.9%) of methadone patients remained in treatment (P =.148). Patients on methadone had a higher mean number of opioid-negative months (6.96 vs. 5.43; P <.001) and mean number of months in treatment (9.38 vs. 8.59; P <.001). On multivariable analysis, methadone maintenance was significantly associated with successful treatment (adjusted odds ratio: 2.10; 95% confidence interval: 1.43-3.07). CONCLUSIONS: Office-based buprenorphine and methadone maintenance programs serve very different populations. Both are effective, but patients on methadone had mildly better treatment outcomes.
BACKGROUND: The purpose of this study was to compare demographic factors and 1-year treatment outcomes of patients treated with buprenorphine or methadone. METHODS: The study included 252 subjects who received a prescription for buprenorphine in an academic internal medicine practice and 252 subjects who enrolled in a methadone maintenance program located on the same campus over the same time frame. Data were collected retrospectively. Patients were classified as "opioid-positive" or "opioid-negative" each month for a year based on urine drug testing and provider assessment. Successful treatment was defined as remaining in treatment after 1 year and achieving 6 or more opioid-negative months. RESULTS:Buprenorphinepatients were more likely to be male, have health insurance, be employed, abuse prescription opioids, and be human immunodeficiency virus (HIV) infected; they were less likely to abuse benzodiazepines. At 12 months, 140 (55.6%) of buprenorphinepatients and 156 (61.9%) of methadonepatients remained in treatment (P =.148). Patients on methadone had a higher mean number of opioid-negative months (6.96 vs. 5.43; P <.001) and mean number of months in treatment (9.38 vs. 8.59; P <.001). On multivariable analysis, methadone maintenance was significantly associated with successful treatment (adjusted odds ratio: 2.10; 95% confidence interval: 1.43-3.07). CONCLUSIONS: Office-based buprenorphine and methadone maintenance programs serve very different populations. Both are effective, but patients on methadone had mildly better treatment outcomes.
Authors: Rachel Springer; Miguel Marino; Steffani R Bailey; Heather Angier; Jean P O'Malley; Megan Hoopes; Stephan Lindner; Jennifer E DeVoe; Nathalie Huguet Journal: Addiction Date: 2019-06-30 Impact factor: 6.526
Authors: Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2018-06-19 Impact factor: 4.492
Authors: Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-10-19 Impact factor: 4.492
Authors: Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet Journal: J Subst Abuse Treat Date: 2016-12-30
Authors: Fabio Lugoboni; Frances Rudnick Levin; Maria Chiara Pieri; Matteo Manfredini; Lorenzo Zamboni; Lorenzo Somaini; Gilberto Gerra Journal: Psychiatry Res Date: 2017-01-21 Impact factor: 3.222
Authors: Michael D Stein; Celeste M Caviness; Kristin Grimone; Daniel Audet; Allison Borges; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2014-11-20